Enliven Therapeutics, Inc./$ELVN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Enliven Therapeutics, Inc.

Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.

Ticker

$ELVN
Sector
Primary listing

Employees

63

ELVN Metrics

BasicAdvanced
$1.2B
-
-$2.00
1.03
-

Bulls say / Bears say

The Phase 1 ENABLE trial for ELVN-001 showed a 47% cumulative major molecular response rate by 24 weeks—41% in patients resistant to tyrosine kinase inhibitors (TKIs)—with a favorable safety profile and no higher risk of cardiovascular toxicity, highlighting its strong potential as a leading therapy for chronic myeloid leukemia (CML).
Goldman Sachs started covering Enliven Therapeutics with a Buy rating and a $37 price target, suggesting more than 60% potential upside. The firm cited strong Phase 1 data for ELVN-001 and characterized Enliven as a compelling investment opportunity in the CML sector.
Enliven’s public offering scheduled for June 2025 is expected to raise about $200 million in gross proceeds, which will notably strengthen its balance sheet and provide enough cash to fund its planned Phase 3 pivotal trial in 2026.
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ELVN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs